Soft Tissue Sarcoma, Version 2.2012

Featured Updates to the NCCN Guidelines

Restricted access

The major changes to the 2012 and 2011 NCCN Guidelines for Soft Tissue Sarcoma pertain to the management of patients with gastrointestinal stromal tumors (GISTs) and desmoid tumors (aggressive fibromatosis). Postoperative imatinib following complete resection for primary GIST with no preoperative imatinib is now included as a category 1 recommendation for patients with intermediate or high risk of recurrence. The panel also reaffirmed the recommendation for preoperative use of imatinib in patients with GISTs that are resectable with negative margins but associated with significant surgical morbidity. Observation was included as an option for patients with resectable desmoid tumors that are small and asymptomatic, not causing morbidity, pain, or functional limitation. Sorafenib is included as an option for systemic therapy for patients with desmoid tumors.

  • 1

    Hirota S, Isozaki K, Moriyama Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577580.

  • 2

    Hirota S, Ohashi A, Nishida T. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660667.

    • Search Google Scholar
    • Export Citation
  • 3

    Heinrich MC, Corless CL, Duensing A. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708710.

  • 4

    Janeway KA, Kim SY, Lodish M. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 2011;108:314318.

    • Search Google Scholar
    • Export Citation
  • 5

    Demetri GD, von Mehren M, Blanke CD. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472480.

    • Search Google Scholar
    • Export Citation
  • 6

    Blanke CD, Demetri GD, von Mehren M. Long-term results from a randomized phase II trial of standardversus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620625.

    • Search Google Scholar
    • Export Citation
  • 7

    von Mehren M, Heinrich MC, Joensuu H. Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST) [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 10016.

    • Search Google Scholar
    • Export Citation
  • 8

    Posner MC, Shiu MH, Newsome JL. The desmoid tumor. Not a benign disease. Arch Surg 1989;124:191196.

  • 9

    Sorensen A, Keller J, Nielsen OS, Jensen OM. Treatment of aggressive fibromatosis: a retrospective study of 72 patients followed for 1-27 years. Acta Orthop Scand 2002;73:213219.

    • Search Google Scholar
    • Export Citation
  • 10

    Eisenberg BL, Harris J, Blanke CD. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009;99:4247.

    • Search Google Scholar
    • Export Citation
  • 11

    Fiore M, Palassini E, Fumagalli E. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol 2009;35:739745.

    • Search Google Scholar
    • Export Citation
  • 12

    Blesius A, Cassier PA, Bertucci F. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer 2011;11:72.

    • Search Google Scholar
    • Export Citation
  • 13

    McAuliffe JC, Hunt KK, Lazar AJF. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009;16:910919.

    • Search Google Scholar
    • Export Citation
  • 14

    Demetri GD, von Mehren M, Antonescu CR. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010;8(Suppl 2):S141.

    • Search Google Scholar
    • Export Citation
  • 15

    Debiec-Rychter M, Sciot R, Le Cesne A. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:10931103.

    • Search Google Scholar
    • Export Citation
  • 16

    Heinrich MC, Owzar K, Corless CL. Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:53605367.

    • Search Google Scholar
    • Export Citation
  • 17

    Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a metaanalysis of 1,640 patients. J Clin Oncol 2010;28:12471253.

    • Search Google Scholar
    • Export Citation
  • 18

    Dematteo RP, Antonescu CR, Chadaram V. Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: safety results from the U.S. Intergroup phase II trial ACOSOG Z9000 [abstract]. J Clin Oncol 2005;23(Suppl 1):Abstract 9009.

    • Search Google Scholar
    • Export Citation
  • 19

    Dematteo RP, Ballman KV, Antonescu CR. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:10971104.

    • Search Google Scholar
    • Export Citation
  • 20

    Joensuu H, Eriksson M, Sundby Hall K. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012;307:12651272.

    • Search Google Scholar
    • Export Citation
  • 21

    DeMatteo RP, Lewis JJ, Leung D. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:5158.

    • Search Google Scholar
    • Export Citation
  • 22

    Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004;11:465475.

    • Search Google Scholar
    • Export Citation
  • 23

    Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg 2006;244:176184.

  • 24

    Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008;39:14111419.

  • 25

    Gold JS, Gonen M, Gutierrez A. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009;10:10451052.

    • Search Google Scholar
    • Export Citation
  • 26

    Ballo MT, Zagars GK, Pollack A. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 1999;17:158167.

    • Search Google Scholar
    • Export Citation
  • 27

    Bonvalot S, Eldweny H, Haddad V. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 2008;34:462468.

    • Search Google Scholar
    • Export Citation
  • 28

    Fiore M, Rimareix F, Mariani L. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 2009;16:25872593.

    • Search Google Scholar
    • Export Citation
  • 29

    Stoeckle E, Coindre JM, Longy M. A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases. Eur J Surg Oncol 2009;35:129134.

    • Search Google Scholar
    • Export Citation
  • 30

    Gounder MM, Lefkowitz RA, Keohan ML. Activity of sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 2011;17:40824090.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1096 841 46
PDF Downloads 69 46 3
EPUB Downloads 0 0 0